UCSF

Enable Medicine Announces Publication in Science Immunology Showing Spatial Transcriptomics Reveal Distinct Mechanisms of Response to Psoriasis Therapy

Retrieved on: 
Monday, January 29, 2024
Technology, Biotechnology, FDA, Health, Other Health, Pharmaceutical, Artificial Intelligence, Other Science, Research, Software, Genetics, Science, Data Management, Clinical Trials, Entrepreneurship, Patient, UCSF, Drug resistance, Associate, MD, PV, Paper, Cytokine, Drug discovery, Skin, Psoriasis, Disease, Doctor of Philosophy, Inflammation, Keratinocyte, Science Immunology, Pharmaceutical industry

The paper titled: " A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response ," details crucial insights into the mechanisms underlying treatment response and resistance in psoriasis patients receiving IL-23 blockade.

Key Points: 
  • The paper titled: " A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response ," details crucial insights into the mechanisms underlying treatment response and resistance in psoriasis patients receiving IL-23 blockade.
  • Psoriasis vulgaris and other chronic inflammatory diseases improve markedly with therapeutic blockade of IL-23 signaling, but the genetic mechanisms underlying clinical responses remain poorly understood.
  • Using single cell transcriptomics, researchers profiled immune cells isolated from lesional psoriatic skin before and during IL-23 blockade.
  • “This study offers unprecedented insights into the molecular mechanisms underlying treatment response and resistance in psoriasis.

More Employers Board Clipper® BayPass, Provide Workers Unlimited Free Transit

Retrieved on: 
Tuesday, January 23, 2024
San Francisco State University, Student, UCSF, State university system, City, Policy, SAN, Housing, University, TMA, MTC, Travel, Metropolitan Transit Commission, University of California, Muni, BART, Transport, Organization, Airline

SAN FRANCISCO, Jan. 23, 2024 /PRNewswire/ -- The Metropolitan Transportation Commission (MTC) this month finalized agreements with the Alameda Transportation Management Association (Alameda TMA) and City of Menlo Park to provide up to a combined 1,900 people with passes for unlimited free travel for one year on any of 24 Bay Area transit agencies. The agreements with the two entities are part of Phase 2 of the Clipper® BayPass program, which is jointly managed by MTC and BART. 

Key Points: 
  • More than 1,700 total participants from more than two dozen member organizations are eligible to participate in Clipper BayPass.
  • MTC teamed with BART and other transit agencies to launch Phase I of the Clipper BayPass pilot in August 2022.
  • Fare coordination and integration is a cornerstone of the Bay Area Transit Transformation Action Plan adopted by MTC in 2021.
  • Transit agencies later in 2024 will expand fare integration with the launch of a pilot program for no-cost and reduced-cost transfers between agencies.

Dr. Rana Baroudi Celebrates One Year as Associate Clinical Professor of Periodontology at UCSF

Retrieved on: 
Tuesday, January 16, 2024
Student, Learning, School, Patient, UCSF, Periodontal disease, Research, Dental school, SAN, University, Mentorship, Environment, Suite, University of California, Dental implant, Teaching, Education, Diagnosis, Dentistry

SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- The University of California, San Francisco (UCSF) School of Dentistry is proud to celebrate Dr. Rana Baroudi's first year as an Associate Clinical Professor of Periodontology. Dr. Baroudi has brought a wealth of experience, expertise, and innovation to the department, significantly enhancing both our academic and clinical offerings.

Key Points: 
  • The University of California, San Francisco (UCSF) School of Dentistry is proud to celebrate Dr. Rana Baroudi's first year as an Associate Clinical Professor of Periodontology.
  • SAN FRANCISCO, Jan. 16, 2024 /PRNewswire-PRWeb/ -- The University of California, San Francisco (UCSF) School of Dentistry is proud to celebrate Dr. Rana Baroudi's first year as an Associate Clinical Professor of Periodontology.
  • Dr. Baroudi has brought a wealth of experience, expertise, and innovation to the department, significantly enhancing both our academic and clinical offerings.
  • As we celebrate this milestone, UCSF looks forward to Dr. Baroudi's ongoing contributions and leadership in the field of periodontology.

Vivalink's Global Impact Spans Over 50 Countries: Enabling Digital Healthcare Solutions Worldwide

Retrieved on: 
Wednesday, January 10, 2024
RPM, ECG, Stanford University, UCSF, Harvard Medical School, Amazon Web Services, Intelligence, University of Oxford, UCLA, Harvard University, Omron, Machine learning, GE HealthCare, Medical device

CAMPBELL, Calif., Jan. 10, 2024 /PRNewswire/ -- Vivalink, a leading provider of digital healthcare solutions, proudly announces significant milestones achieved in 2023, reinforcing its commitment to advancing the adoption of remote patient monitoring in healthcare and clinical trials. The company's innovative Biometrics Data Platform, powered by Amazon Web Services, enables digital healthcare innovations with unparalleled data insights, contributing to breakthroughs in artificial intelligence and machine learning applications for healthcare.

Key Points: 
  • Vivalink's digital healthcare network expands globally with more than 300 partnerships worldwide, reaffirming its role as the preferred choice for remote patient monitoring.
  • Key achievements for Vivalink in 2023 include:
    3X year-over-year sales growth, a testament to the increasing demand for Vivalink's remote patient monitoring solutions.
  • Investment from a group of investors including Niterra to drive continued innovation in digital healthcare and remote patient monitoring.
  • As the adoption of RPM solutions continues to grow worldwide, the technology's real promise is to provide healthcare for all.

Kindbody Opens in Walnut Creek; Marks Four Years of Serving Patients and Employers with Transformative Reproductive Healthcare in the San Francisco Bay Area

Retrieved on: 
Tuesday, January 9, 2024
Silicon, Northwestern University, Patient, UCSF, Fertility, Infertility, IVF, REI, University, Gynaecology, Biomedical engineering, Obstetrics and gynaecology, San Francisco General Hospital, Hospital, Obstetrics, Parent, Georgia Tech, El Camino Real, Nursing

NEW YORK, Jan. 9, 2024 /PRNewswire/ -- Kindbody, the leading national fertility clinic network and global family-building benefits provider for employers, today announced the opening of Kindbody East Bay, its state-of-the-art clinic and IVF lab at 1700 N. Main Street in Walnut Creek, CA. The announcement comes at a time of extraordinary growth for the company which owns and operates 34 clinics nationwide, including a state-of-the-art fertility clinic and IVF lab in downtown San Francisco at 88 Sutter Street and a Silicon Valley location at 4756 El Camino Real in Los Altos. Kindbody East Bay was built to meet the growing demand for comprehensive fertility and family-building benefits that cover the full spectrum of reproductive care by Bay Area employers. The clinic is led by Dr. Geraldine Ekpo, a fertility specialist who is board-certified in both reproductive endocrinology and obstetrics and gynecology.

Key Points: 
  • Kindbody East Bay was built to meet the growing demand for comprehensive fertility and family-building benefits that cover the full spectrum of reproductive care by Bay Area employers.
  • The opening of Kindbody East Bay follows four years of serving employers and patients throughout the San Francisco Bay Area.
  • Dr. Ekpo is currently accepting new patients at the East Bay location and will continue to serve patients in San Francisco.
  • Employers who wish to learn more about how Kindbody delivers the best patient experience and outcomes while reducing healthcare costs can contact [email protected] .

Capstan Therapeutics Appoints Ramin Farzaneh-Far, M.D., as Chief Medical Officer and Announces Key Business Leadership Promotion

Retrieved on: 
Monday, January 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, University, MAS, Autoimmune disease, Business, Drug development, Messenger, Acquisition, Roche, MBA, Therapy, UCB, David G. Booth, University College London, Growth, IPO, Cell, Patient, Corporate development, Gilead Sciences, UCSF, Senior, Pharmaceutical industry

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development.
  • He previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences.
  • “I am pleased to announce Miguel’s promotion in recognition of his contributions to the organization.”
    Mr. Arcinas joined Capstan in 2021 as the company’s Vice President of Corporate Development.
  • He has over 15 years of multi-disciplinary experience in biotech corporate strategy, business development, investor relations, and clinical operations.

Multiply Labs Releases Preprint Data Showing That Automated and Manual Cell Expansion Processes Are Statistically Equivalent

Retrieved on: 
Friday, January 5, 2024
Research, Pharmaceutical, Robotics, Technology, Other Manufacturing, Science, Engineering, Biotechnology, Other Technology, Manufacturing, Other Science, Health, Multimedia, FDA, Staphylococcus epidermidis, Thermo Fisher Scientific, GMP, Gene, Charles River Laboratories, Multiplication, Therapy, Automation, Cell, UCSF, Skin

This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.

Key Points: 
  • This data demonstrates that automated cell therapy manufacturing outcomes (cell quantity and quality) using Multiply Labs’ proof-of-concept robotic system are statistically equivalent to that of a process performed manually.
  • “This data demonstrates that manufacturers can confidently automate their existing processes for cell expansion, without making significant modifications to the process itself, effectively minimizing bioprocess and regulatory risks.
  • In addition to cell count and viability successes, none of the robotic cell expansion samples were contaminated.
  • The research, titled “Development of a robotic cluster for automated and scalable cell therapy manufacturing,” is currently under review.

AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological Diseases

Retrieved on: 
Wednesday, January 3, 2024
Arthritis, Quality of life, University, Canadian Aviation Regulations, Honorary, CD20, SLE, SAB, Society, Innovation, Cancer, Autoimmune disease, UCSF, Skin condition, Hospital for Special Surgery, B cell, Weill Cornell Medicine, Safety, Journal, Lupus nephritis, Human musculoskeletal system, Biomarker, Arthritis Foundation, Intramural sports, Patient, Hospital, Preventive healthcare, Division, Research, Jean, BCMA, Postgraduate education, Catholic League (German), Rheumatoid arthritis, Lupus Research Alliance, Conditional sentence, Bangladesh Technical Education Board, American College, Cell, CD19, Lee, Culture, Pharmaceutical industry

These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."

Key Points: 
  • These four industry experts are distinguished scientific leaders with vast experience in the autoimmune disease field."
  • Members of the SAB include:
    Peter Lipsky, M.D., served on the Board of Directors of the American College of Rheumatology.
  • She was President of the American College of Rheumatology, President of the Henry Kunkel Society, and Chair of the Scientific Advisory Board of the Lupus Research Alliance.
  • "AbelZeta is advancing promising new therapies for inflammatory and immunological diseases through innovative cell therapy platforms that provide custom-tailored treatment for each individual patient.

BridgeBio announces FDA clearance of IND application for BBO-8520, a first-in-class direct inhibitor of KRASG12C (ON)

Retrieved on: 
Wednesday, January 3, 2024
Switch II, Lung cancer, Neoplasm, IND, FDA, GTP, FNL, Cancer, Patient, Switch, UCSF, Pharmaceutical industry

BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity.

Key Points: 
  • BBO-8520 binds covalently to the Switch II pocket in both the GTP-bound (ON) and GDP-bound (OFF) state conformations of KRASG12C, leading to rapid and robust inhibition of KRASG12C activity.
  • BBO-8520 drives substantial tumor growth inhibition in multiple preclinical models, even after emergence of resistance to sotorasib, an FDA approved (OFF) state inhibitor of KRASG12C.
  • “BBO-8520 is the most potent G12C inhibitor with an IND, and the only compound that directly binds and targets the ON state.
  • Enrollment of patients with KRASG12C mutant non-small cell lung cancer into the ONKORAS-101 trial is expected to begin in H1 of this year.

Allurion’s Digital Platform Gains Traction with Expanded Strategic Partnership

Retrieved on: 
Tuesday, January 2, 2024
Biotechnology, Men, Diabetes, Health, Family, Consumer, Other Health, Surgery, Telemedicine, Virtual Medicine, Medical Devices, Hospitals, Other Consumer, Fitness & Nutrition, Women, Entrepreneurship, Hospital, Bariatric surgery, Software, Weight loss, Federal Medical Centres, AI, Mayo Clinic, Obesity, Growth, Patient, VCS, UCSF, Nursing

The end patients include not only those treated with the Allurion Balloon, but also those receiving bariatric surgery and taking GLP-1 anti-obesity medications.

Key Points: 
  • The end patients include not only those treated with the Allurion Balloon, but also those receiving bariatric surgery and taking GLP-1 anti-obesity medications.
  • The expanded agreement illustrates the momentum Allurion is seeing with its Virtual Care Suite and is an example of the growing pipeline of commercialization opportunities for Allurion’s digital platform since launching Coach Iris—Allurion’s 24/7 AI-powered weight loss coach—in October 2023.
  • With what it believes is a sizable opportunity ahead, Allurion has strengthened its team with the addition of Brian Conyer to lead commercialization of Allurion’s digital assets.
  • “The demand for weight loss solutions has never been higher, and I believe Allurion’s VCS digital platform will become an essential part of any successful weight loss practice that wants to operate at scale.”